Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

Lignende værker

• Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
  af: Fan, Bin, et al.
  Udgivet: (2019)
• Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
  af: Choe, Sung, et al.
  Udgivet: (2020)
• Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
  af: Popovici-Muller, Janeta, et al.
  Udgivet: (2018)
• Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
  af: Roboz, Gail J., et al.
  Udgivet: (2020)
• The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
  af: Anh Huan Vo, et al.
  Udgivet: (2022-01-01)